Vol. 6 No. 5 (2026): May
Reimbursement Reviews

Seladelpar (Lyvdelzi)

decorative image of the issue cover

Published May 5, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses seladelpar (Lyvdelzi), 10 mg, capsule, oral.
  • Indication: For the treatment of PBC in combination with UDCA in adults who have an inadequate response to UDCA alone, or as monotherapy in adults unable to tolerate UDCA.